Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.46 |
| ▸ | FBP1 | P09467 | 7/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094551 | 0.90 | HDAC1 (0.47) | HDAC1HDAC2HDAC3FBP1ABCB11 | |
| SCHEMBL6094343 | 0.82 | ERN1 (0.50) | HDAC1HDAC2HDAC3FBP1TNFRSF1A | |
| SCHEMBL6094560 | 0.82 | TNFRSF1A (0.48) | HDAC1HDAC2HDAC3FBP1KMT2A | |
| SCHEMBL6092109 | 0.81 | ALDH1A1 (0.41) | HDAC1HDAC2HDAC3FBP1ABCB11 | |
| SCHEMBL14110370 | 0.80 | FBP1 (0.49) | FBP1ABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL4685610 | 0.77 | FBP1 (0.53) | FBP1ABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL6091552 | 0.76 | ALDH1A1 (0.41) | HDAC1HDAC2HDAC3FBP1ABCB11 | |
| SCHEMBL6093858 | 0.75 | ALDH1A1 (0.47) | KCNH2KMT2ATNFRSF1A | |
| SCHEMBL6092795 | 0.75 | FBP1 (0.46) | HDAC1HDAC2HDAC3FBP1ABCB11 | |
| SCHEMBL6091509 | 0.74 | TNFRSF1A (0.37) | HDAC1HDAC2HDAC3TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | HDAC1 1097/4885HDAC2 651/4885HDAC3 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.